Effects of gestational diabetes mellitus with different birth weight on genetic metabolism of newborns. A retrospective cohort study
Abstract
Objectives: To investigate the effects of gestational diabetes mellitus (GDM) with different birth weights on neonatal genetic metabolism.
Material and methods: 1252 patients with GDM diagnosed at Changzhou Maternal and Child Health Care Hospital from 2017 to 2021 were categorized into three groups: fetal growth restriction (G1), normal birth weight (G2), and macrosomia (G3). The levels of amino acids, free carnitine (CO) and acylcarnitine in neonates were detected using tandem mass spectrometry.
Results: There were no differences in age, height, predelivery weight or gravida across groups. G3 had the highest parity and fasting blood glucose levels (p < 0.0001). G1 exhibited the highest rates of cesarean section, neonatal asphyxia, and insulin utilization (p < 0.0001). Neonatal genetic metabolism analysis revealed that in G1 citrulline levels were the highest, with significantly elevated levels of leucineornithine and valine (p < 0.001). CO was also the highest (p < 0.001). The levels of isovalerylcarnitine, octanoylcarnitine and 18-carbodienoylcarnitine increased, while malonylcarnitine/3-hydroxy-butyrylcarnitine, hexadecanoylcarnitine, hexadecenoylcarnitine, 3-hydroxy-hexadecenoylcarnitine and 3-hydroxy-hexadecanoylcarnitine decreased (p < 0.05). In G2, methionine levels decreased (p < 0.001), whereas decenoylcarnitine, dodecanoylcarnitine, dodecenoylcarnitine and myristoylcarnitine levels increased (p < 0.001). In G3, proline decreased significantly (p < 0.001), and CO was the lowest (p < 0.001). Propionylcarnitine and octenoylcarnitine levels increased, whereas butyrylcarnitine decreased (p < 0.05).
Conclusions: Gestational diabetes mellitus with different birth weights influences neonatal genetic metabolism in distinct ways. Therefore, neonatal screening for inherited metabolic disorders provides insights into the metabolic levels of offspring of patients with GDM in early life.
Keywords: gestational diabetes mellitusmacrosomiafetal growth restrictionneonatal disease screening
References
- Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018; 138: 271–281.
- Gorban de Lapertosa S, Alvariñas J, Elgart JF, et al. EduGest group. The triad macrosomia, obesity, and hypertriglyceridemia in gestational diabetes. Diabetes Metab Res Rev. 2020; 36(5): e3302.
- El-Hattab AW, Almannai M, Sutton VR. Newborn Screening: History, Current Status, and Future Directions. Pediatr Clin North Am. 2018; 65(2): 389–405.
- Sweeting A, Wong J, Murphy HR, et al. A Clinical Update on Gestational Diabetes Mellitus. Endocr Rev. 2022; 43(5): 763–793.
- Poon LC, McIntyre HD, Hyett JA, et al. FIGO Pregnancy and NCD Committee. The first-trimester of pregnancy - A window of opportunity for prediction and prevention of pregnancy complications and future life. Diabetes Res Clin Pract. 2018; 145: 20–30.
- Sun YY, Juan J, Xu QQ, et al. Increasing insulin resistance predicts adverse pregnancy outcomes in women with gestational diabetes mellitus. J Diabetes. 2020; 12(6): 438–446.
- Rosinha PM, Dantas RA, Alves MI, et al. Body mass index and gestational weight gain: relevance in gestational diabetes and outcomes - A retrospective cohort study. Arch Endocrinol Metab. 2022; 66(2): 261–268.
- Soares MJ, Iqbal K, Kozai K. Hypoxia and Placental Development. Birth Defects Res. 2017; 109(17): 1309–1329.
- Scholtens DM, Bain JR, Reisetter AC, et al. HAPO Study Cooperative Research Group. Metabolic Networks and Metabolites Underlie Associations Between Maternal Glucose During Pregnancy and Newborn Size at Birth. Diabetes. 2016; 65(7): 2039–2050.
- Fabie NA, Pappas KB, Feldman GL. The Current State of Newborn Screening in the United States. Pediatr Clin North Am. 2019; 66(2): 369–386.
- Yang Y, Yu B, Long W, et al. Investigating the changes in amino acid values in premature infants: a pilot study. J Pediatr Endocrinol Metab. 2018; 31(4): 435–441.
- Pakula MM, Maier TJ, Vorup-Jensen T. Insight on the impacts of free amino acids and their metabolites on the immune system from a perspective of inborn errors of amino acid metabolism. Expert Opin Ther Targets. 2017; 21(6): 611–626.
- Zhao H, Li H, Chung AC, et al. Large-Scale Longitudinal Metabolomics Study Reveals Different Trimester-Specific Alterations of Metabolites in Relation to Gestational Diabetes Mellitus. J Proteome Res. 2019; 18(1): 292–300.
- Chen Y, Wang Na, Dong X, et al. Associations between serum amino acids and incident type 2 diabetes in Chinese rural adults. Nutr Metab Cardiovasc Dis. 2021; 31(8): 2416–2425.
- Lin Y, Lin B, Chen Y, et al. Biochemical and genetic characteristics of patients with primary carnitine deficiency identified through newborn screening. Orphanet J Rare Dis. 2021; 16(1): 503.
- Schupper A, Almashanu S, Coster D, et al. Metabolic biomarkers of small and large for gestational age newborns. Early Hum Dev. 2021; 160: 105422.
- Almannai M, Alfadhel M, El-Hattab AW. Carnitine Inborn Errors of Metabolism. Molecules. 2019; 24(18).
